Within the context of gene and RNA-based therapies for AD and other dementias, at present therapies are specific to a single gene mutation (e.g., GRN) or proteinopathy (e.g., MAPT) to ensure clear evidence regarding safety and efficacy. This evidence concerns the gene MAPT and dementia.